Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Traumatic brain injury: progress and challenges in prevention, clinical care, and research

AIR Maas, DK Menon, GT Manley, M Abrams… - The Lancet …, 2022 - thelancet.com
Executive summary Traumatic brain injury (TBI) has the highest incidence of all common
neurological disorders, and poses a substantial public health burden. TBI is increasingly …

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

B Raman, DA Bluemke, TF Lüscher… - European heart …, 2022 - academic.oup.com
Emerging as a new epidemic, long COVID or post-acute sequelae of coronavirus disease
2019 (COVID-19), a condition characterized by the persistence of COVID-19 symptoms …

Redefining critical illness

DM Maslove, B Tang, M Shankar-Hari, PR Lawler… - Nature medicine, 2022 - nature.com
Research and practice in critical care medicine have long been defined by syndromes,
which, despite being clinically recognizable entities, are, in fact, loose amalgams of …

Simvastatin in critically ill patients with Covid-19

REMAP-CAP Investigators - New England Journal of Medicine, 2023 - Mass Medical Soc
Background The efficacy of simvastatin in critically ill patients with coronavirus disease 2019
(Covid-19) is unclear. Methods In an ongoing international, multifactorial, adaptive platform …

Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium

DA Gorog, RF Storey, PA Gurbel, US Tantry… - Nature Reviews …, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with …

AC Spyropoulos, M Goldin, D Giannis… - JAMA internal …, 2021 - jamanetwork.com
Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid …

M Sholzberg, GH Tang, H Rahhal, M AlHamzah… - bmj, 2021 - bmj.com
Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre …

E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar… - The Lancet, 2022 - thelancet.com
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …

2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary

TF Chao, B Joung, Y Takahashi, TW Lim… - Thrombosis and …, 2022 - thieme-connect.com
The consensus of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in
atrial fibrillation (AF) has been published in 2017 which provided useful clinical guidance for …